OKYO Pharma Announces Chairman and Founder Acquires Shares

Rhea-AI Summary

OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares on NASDAQ on Dec 3, 2025.

The purchase increases the Chairman's total holding to 10,491,746 shares. The company is developing urcosimod for neuropathic corneal pain, a condition with no FDA-approved therapy.

Positive

• Insider purchase of 27,051 shares on Dec 3, 2025
• Total insider holding increased to 10,491,746 shares

Negative

• None.

LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares.

About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.

About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.

For further information, please visit www.okyopharma.com.

Inquiries:

Business Development & Investor Relations

Paul Spencer

+44 (0)20 7495 2379

FAQ

What did OKYO (NASDAQ: OKYO) announce on Dec 3, 2025 about insider buying?

Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, acquired 27,051 ordinary shares on Dec 3, 2025.

How many OKYO shares does Chairman Gabriele Cerrone now hold after the Dec 3, 2025 purchase?

His total beneficial holding is reported as 10,491,746 shares.

Which entity executed the OKYO share purchase reported Dec 3, 2025?

The purchase was made by Panetta Partners Limited, an entity in which the Executive Chairman has a beneficial interest.

What program or drug is OKYO Pharma developing mentioned in the Dec 3, 2025 notice?

The company is developing urcosimod to treat neuropathic corneal pain (NCP), a condition without an FDA-approved therapy.

Where were the 27,051 OKYO shares purchased as disclosed on Dec 3, 2025?

The shares were acquired on NASDAQ.